bluebird bio Inc. (NASDAQ:BLUE) saw an upside of 4.19% to close Monday at $19.90 after adding $0.8 on the day. The 5-day average trading volume is 710,440 shares of the company’s common stock. It has gained $19.96 in the past week. An average of 917,700 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,245,938.
BLUE’s 1-month performance is 11.30% or $2.02 on its low of $17.27 reached on 09/16/21. The company’s shares have touched a 52-week low of $17.14 and high of $59.32, with the stock’s rally to the 52-week high happening on 01/12/21. YTD, BLUE has lost -54.01% or -$23.37. However, the current price is down -66.45%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Jun 04, 130 days have gone by since the last insider trading activity for bluebird bio Inc. (BLUE). Obenshain Andrew (President of SGD) most recently sold 511 shares at $30.75 per share on Jun 04. This transaction cost the insider $15,715. Chief Scientific Officer, Gregory Philip D, sold 39 shares at a price of $30.15 on May 03. Then, on May 03, President of SGD Obenshain Andrew sold 29 shares at a price of $30.15 per share. This transaction amounted to $874.
bluebird bio Inc. (BLUE) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.BLUE stock has a beta of 1.50. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 26.48 while the price-to-book (PB) in the most recent quarter is 1.36.
bluebird bio Inc.’s quick ratio for the period ended June 29 was 3.60, with the current ratio over the same period at 3.60 meaning that BLUE stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00. In terms of profitability, the gross margin trailing 12 months is 59.40%. The trailing 12-month EBITDA margin is -243.35%. The firm’s gross profit as reported stood at $245.34 million against revenue of $250.73 million.
For the quarterly period ending June 29 this year, bluebird bio Inc.’s cash and short-term investments amounted to $486.23 million against total debt of $198.6 million. Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected BLUE to announce -$3.25 per share in earnings in its latest quarter, but it posted -$3.58, representing a -10.20% surprise. EBITDA for the quarter stood at more than -$234.84 million. BLUE stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 469.9 million, with total debt at $198.6 million. Shareholders hold equity totaling $67.58 million
Let’s look briefly at bluebird bio Inc. (BLUE) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 67.45% to suggest the stock is trending Neutral, with historical volatility in this time period at 37.01%.
The stock’s 5-day moving average is $18.93, reflecting a +7.92% or $1.46 change from its current price. BLUE is currently trading +8.80% above its 20-day SMA, -32.38% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -21.68% and -56.75% respectively.
Stochastic %K and %D was 73.71% and 58.48% and the average true range (ATR) pointed at 0.79. The RSI (14) points at 59.21%, while the 14-day stochastic is at 97.51% with the period’s ATR at 0.81. The stock’s 9-day MACD Oscillator is pointing at 0.37 and 0.41 on the 14-day charts.
Analysts offering their rating for BLUE stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate BLUE as a “sell,”, while 17 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 3 have offered a “buy” rating.
What is BLUE’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $18.00 and a high of $37.00, with their median price target at $22.00. Looking at these predictions, the average price target given by analysts is for bluebird bio Inc. (BLUE) stock is $22.80.